Meridian, a subsidiary of Pfizer that manufactures EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors, continues to experience manufacturing constraints affecting U.S. supply. Pfizer takes very seriously the importance of EpiPen to everyone who needs it, and we are working tirelessly to increase production and expedite shipments as rapidly as possible. Currently, supplies will vary from pharmacy to pharmacy, and we cannot guarantee that product will be available at all pharmacies.

We are actively exploring several options that would help stabilize supply. We will continue to provide updates, including timing for resolution, as we have them.

We understand the challenges this situation continues to pose to patients. Ensuring continuity of the supply of our medicines is paramount.

Because EpiPen is distributed and sold by Mylan Specialty L.P. in the U.S., medical professionals should direct questions about EpiPen usage to Mylan at 800-796-9526.

Mylan’s statement is available here.

ADDITIONAL INFORMATION FOR PATIENTS
Please be assured that your health and safety are our highest priorities, and that we continually strive to ensure the safety, quality and efficacy of the EpiPen products we make. If you have supplies of unexpired EpiPen in quantities deemed medically appropriate by your doctor, we urge prudence in refilling additional prescriptions for any dosage of EpiPen during this temporary period of manufacturing constraints, in order to help ensure that other patients have access to this medication.

# # # # #